Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLZ89P)

• Drug Name: KN-62 Drug Info
• Synonyms: KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5312126
  ChEBI ID: CHEBI:131159
  CAS Number: CAS 127191-97-3
  TTD Drug ID: DMLZ89P

Molecule-Related Drug Atlas

Drug(s) Targeting LCK tyrosine protein kinase (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[5]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[7]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[2]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[2]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[8]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[2]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[9]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Protein kinase C alpha (PRKCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[11]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[12]
PMID28460551-Compound-3	DMA1FRM	N. A.	N. A.	Patented	[13]
ISIS 3521	DMZFS69	N. A.	N. A.	Discontinued in Phase 2	[14]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[15]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[16]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[17]
Acteoside	DM0YHKB	Nephritis	GB40	Terminated	[18]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[19]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Stress-activated protein kinase JNK1 (JNK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKP-1339	DM5AWK1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[21]
7-azaindole derivative 1	DMQL5B7	N. A.	N. A.	Patented	[21]
7-azaindole derivative 5	DMV3H98	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-P6	DMNDVC9	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-J3	DM17P3F	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-P1	DMD8AX6	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-O3	DMVOWS5	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[21]

Drug(s) Targeting Rho-associated protein kinase 1 (ROCK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[22]
SAR-407899	DMF95KD	Diabetic nephropathy	GB61.Z	Phase 2	[23]
H-1152	DM8XH3S	Pulmonary arterial hypertension	BB01.0	Phase 2	[24]
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[25]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[26]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[27]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[27]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[27]
PMID28048944-Compound-4	DMJAUWG	N. A.	N. A.	Patented	[27]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[27]

Drug(s) Targeting Stress-activated protein kinase 2b (p38 beta)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[28]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[28]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[2]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[2]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[8]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[2]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[2]
STAUROSPORINONE	DMU2H4K	Discovery agent	N.A.	Investigative	[2]
KT-5720	DM9J50F	Discovery agent	N.A.	Investigative	[2]
L-779450	DM51B74	Discovery agent	N.A.	Investigative	[29]

Drug(s) Targeting Extracellular signal-regulated kinase 2 (ERK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[30]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[31]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[32]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[33]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[34]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[35]
LY3214996	DMFDAY7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[36]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[37]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[38]
SB220025	DMSBUET	Arthritis	FA20	Terminated	[39]

Drug(s) Targeting Checkpoint kinase-1 (CHK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2603618	DMCXRZF	Pancreatic cancer	2C10	Phase 2	[40]
UCN-01	DMUNJZB	Non-small-cell lung cancer	2C25.Y	Phase 2	[41]
SCH-900776	DM67EMK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[42]
LY2606368	DM4XMF7	Ovarian cancer	2C73	Phase 2	[36]
LY2880070	DMADEHZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[43]
RG7741	DMK6P9J	Lymphoma	2A80-2A86	Phase 1	[44]
GDC-0425	DMDZ26X	Lymphoma	2A80-2A86	Phase 1	[45]
AZD7762	DM1FW0C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[46]
MK-8776	DMAS1RB	Hodgkin lymphoma	2B30	Phase 1	[47]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[48]

Drug(s) Targeting P2X purinoceptor 7 (P2RX7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CE-224535	DMFCLT6	Arthralgia	ME82	Phase 2/3	[49]
AZD9056	DMJGYPK	Chronic obstructive pulmonary disease	CA22	Phase 2	[46]
LY3857210	DMZO2V2	Pain	MG30-MG3Z	Phase 2	[50]
BIL010t	DMV1EA9	Alzheimer disease	8A20	Phase 1/2	[51]
EVT 401	DMOG8IE	Rheumatoid arthritis	FA20	Phase 1	[52]
SGM-1019	DMDAHEL	Inflammatory bowel disease	DD72	Phase 1	[53]
GSK1482160	DMWDQOV	Pain	MG30-MG3Z	Phase 1	[54]
JNJ-55308942	DM0QZJX	Anhedonia	MB24.2	Phase 1	[51]
JNJ-54175446	DMQ5ZVK	Major depressive disorder	6A70.3	Phase 1	[55]
JNJ-479655	DMDU6GN	Alzheimer disease	8A20	Clinical trial	[56]

Drug(s) Targeting Serine/threonine-protein kinase Sgk1 (SGK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[2]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[2]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[8]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[2]
CGP-57380	DMFPOUC	Discovery agent	N.A.	Investigative	[7]
GSK-650394	DMNRP2L	Prostate cancer	2C82.0	Investigative	[57]

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[54]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[54]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[58]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[28]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[54]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[21]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[21]

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[36]
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[36]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[36]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[5]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[59]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[60]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[61]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[62]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[36]
Triciribine prodrug	DMBN1XS	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[61]

Drug(s) Targeting MAP kinase p38 (MAPK12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SM-101	DMFX9O6	Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[63]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[64]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[65]
KC706	DMBX6C7	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[66]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[67]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[2]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[2]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[8]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[2]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Ribosomal protein S6 kinase beta-1 (S6K1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[36]
NNI-362	DMPCV65	Alzheimer disease	8A20	Phase 1	[68]
PF-4708671	DMO0892	Ulcerative colitis	DD71	Clinical trial	[69]
PMID27410995-Compound-Figure3c	DMDQMZT	N. A.	N. A.	Patented	[70]
Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1	DM6O2Q9	N. A.	N. A.	Patented	[70]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[2]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[71]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[8]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[2]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[2]

Drug(s) Affected By MAP kinase-activated protein kinase 2 (MAPKAPK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[76]
Sorbitol	DMAN0DE	Constipation	DD91.1	Approved	[72]
Bortezomib	DMNO38U	Leukemia		Approved	[77]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[78]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[79]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[80]

Drug(s) Affected By Glycogen synthase kinase-3 beta (GSK3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[81]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[82]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[83]
Selenium	DM25CGV	N. A.	N. A.	Approved	[84]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[85]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[86]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[87]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[90]

Drug(s) Affected By MAP kinase-activated protein kinase 5 (MAPKAPK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[91]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[92]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[93]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[94]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[94]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[95]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[96]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[97]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[98]
PMID26560530-Compound-35	DMO36RL	N. A.	N. A.	Patented	[2]

Drug(s) Affected By Integrin alpha-M (ITGAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[99]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[101]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[102]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[103]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[104]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[105]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[106]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[107]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[108]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[2]
Extracellular signal-regulated kinase 2 (ERK2)	TT4TQBX	MK01_HUMAN	Inhibitor	[2]
LCK tyrosine protein kinase (LCK)	TT860QF	LCK_HUMAN	Inhibitor	[2]
MAP kinase p38 (MAPK12)	TTYT93M	MK12_HUMAN	Inhibitor	[2]
P2X purinoceptor 7 (P2RX7)	TT473XN	P2RX7_HUMAN	Inhibitor	[3]
Protein kinase C alpha (PRKCA)	TTFJ8Q1	KPCA_HUMAN	Inhibitor	[2]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[2]
Rho-associated protein kinase 1 (ROCK1)	TTZN7RP	ROCK1_HUMAN	Inhibitor	[2]
Ribosomal protein S6 kinase beta-1 (S6K1)	TTG0U4H	KS6B1_HUMAN	Inhibitor	[2]
Serine/threonine-protein kinase Sgk1 (SGK1)	TTTV8EJ	SGK1_HUMAN	Inhibitor	[2]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[2]
Stress-activated protein kinase 2b (p38 beta)	TT73U6C	MK11_HUMAN	Inhibitor	[2]
Stress-activated protein kinase JNK1 (JNK1)	TT0K6EO	MK08_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Gene/Protein Processing	[2]
Integrin alpha-M (ITGAM)	OTAG6HWU	ITAM_HUMAN	Gene/Protein Processing	[4]
MAP kinase-activated protein kinase 2 (MAPKAPK2)	OT460SBO	MAPK2_HUMAN	Gene/Protein Processing	[2]
MAP kinase-activated protein kinase 5 (MAPKAPK5)	OTAZHPVK	MAPK5_HUMAN	Gene/Protein Processing	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6001).
• [2] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [3] Synthesis and structure-activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6053-8.
• [4] CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. J Clin Invest. 2007 May;117(5):1412-21. doi: 10.1172/JCI30779. Epub 2007 Apr 12.
• [5] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [6] National Cancer Institute Drug Dictionary (drug id 596693).
• [7] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [8] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [9] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [10] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [11] Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
• [12] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [13] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [14] Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
• [15] Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
• [16] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [17] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [18] Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
• [19] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
• [21] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [22] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [23] The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
• [24] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [25] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [26] Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
• [27] Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
• [28] Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
• [29] The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
• [30] DOI: 10.1158/1538-7445.AM2015-4693
• [31] Clinical pipeline report, company report or official report of HaiHe Biopharma.
• [32] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [33] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [34] ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
• [35] National Cancer Institute Drug Dictionary (drug name JSI1187).
• [36] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [37] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [38] Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
• [39] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [40] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
• [41] Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
• [42] Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
• [43] A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
• [44] National Cancer Institute Drug Dictionary (drug id 730054).
• [45] Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
• [46] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [47] Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
• [48] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [49] Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
• [50] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [51] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [52] Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
• [53] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [54] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [55] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [56] Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.
• [57] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040).
• [58] Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
• [59] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [60] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [61] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [62] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [63] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [64] P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
• [65] Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
• [66] KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
• [67] Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
• [68] Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease. Stem Cell Res Ther. 2021 Jan 13;12(1):59.
• [69] Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
• [70] Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
• [71] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [72] The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J Biol Chem. 1998 Apr 17;273(16):9373-7. doi: 10.1074/jbc.273.16.9373.
• [73] Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009 Feb 27;256(3):183-90. doi: 10.1016/j.tox.2008.11.016. Epub 2008 Nov 28.
• [74] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [75] Pregnane X receptor PXR activates the GADD45beta gene, eliciting the p38 MAPK signal and cell migration. J Biol Chem. 2011 Feb 4;286(5):3570-8. doi: 10.1074/jbc.M110.179812. Epub 2010 Dec 2.
• [76] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [77] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [78] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [79] Ornithine decarboxylase antizyme upregulates DNA-dependent protein kinase and enhances the nonhomologous end-joining repair of DNA double-strand breaks in human oral cancer cells. Biochemistry. 2007 Aug 7;46(31):8920-32. doi: 10.1021/bi7000328. Epub 2007 Jul 14.
• [80] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [81] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [82] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [83] The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact. 2019 Sep 1;310:108688. doi: 10.1016/j.cbi.2019.06.001. Epub 2019 Jun 4.
• [84] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [85] Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
• [86] Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
• [87] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [88] Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 2010 Oct 6;188(1):75-85. doi: 10.1016/j.cbi.2010.06.001. Epub 2010 Jun 9.
• [89] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [90] NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2.
• [91] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [92] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [93] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [94] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [95] The specificities of protein kinase inhibitors: an update. Biochem J. 2003 Apr 1;371(Pt 1):199-204. doi: 10.1042/BJ20021535.
• [96] A high concentration of genistein down-regulates activin A, Smad3 and other TGF-beta pathway genes in human uterine leiomyoma cells. Exp Mol Med. 2012 Apr 30;44(4):281-92.
• [97] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [98] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [99] Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem. 2002 Jul 19;277(29):26012-20. doi: 10.1074/jbc.M201803200. Epub 2002 Apr 29.
• [100] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [101] JWA, a novel signaling molecule, involved in all-trans retinoic acid induced differentiation of HL-60 cells. J Biomed Sci. 2006 May;13(3):357-71. doi: 10.1007/s11373-005-9068-0. Epub 2006 Feb 9.
• [102] Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J Lipid Res. 2008 Apr;49(4):763-72. doi: 10.1194/jlr.M700293-JLR200. Epub 2008 Jan 7.
• [103] Comparative study of the effects of ziram and disulfiram on human monocyte-derived macrophage functions and polarization: involvement of zinc. Cell Biol Toxicol. 2021 Jun;37(3):379-400. doi: 10.1007/s10565-020-09540-6. Epub 2020 Jul 25.
• [104] Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med. 2007;45(2):193-9.
• [105] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [106] Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010 Apr 12;207(4):731-50. doi: 10.1084/jem.20091488. Epub 2010 Apr 5.
• [107] MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. PLoS One. 2013 Jun 25;8(6):e66915. doi: 10.1371/journal.pone.0066915. Print 2013.
• [108] [Analysis of in vitro anti-leukemia effect of 5-aza-2'-deoxycitydine]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008 Apr;33(4):344-52.